

**S1 Table : Association between SES and access to a second-line DMT for RRMS patients with a potential indication of second-line DMT after a 5-years delay between first and second line DMT.**

<b>Factors</b>	<b>HR [IC 95%]</b>	<b>p-value</b>
<b>Gender</b>		0.6163
Males	1.00 (Reference)	
Females	0.91 [0.62-1.33]	
<b>Age at disease onset</b>		0.369
[15-25 years]	1.00 (Reference)	
[26-35 years]	0.74 [0.49-1.11]	
[36-45 years]	0.78 [0.48-1.28]	
>45 years	0.54 [0.21-1.39]	
<b>County of residence at diagnosis</b>		0.1472
Manche	1.00 (Reference)	
Calvados	0.72 [0.48-1.07]	
Orne	0.61 [0.35-1.06]	
<b>Period of diagnosis</b>		0.3818
1982-2000	1.00 (Reference)	
2001-2011	1.31 [0.72-2.37]	
<b>Year of disease onset</b>	1.16 [1.1-1.23]	<0.001
<b>EDI<sup>(a)</sup> (quintiles combined)</b>		
Q2-Q5	1.00 (Reference)	
Q1	2.13 [1.07-4.22]	0.0391

<sup>(a)</sup> Multivariate Cox model for studying EDI effect was performed using EDI as time varying covariate that allows taking into consideration the interaction between EDI and time. (tvc function of STATA ® software)

DMT: Disease Modifying Treatment

RRMS: Relapsing Remitting Multiple Sclerosis

HR: Hazard Ratio

CI: Confidence Interval

EDI: European Deprivation Index